1.BranwellVHetal.Acomparisonoftwoshortintensiveadjuvantchemotherapyregimensinoperableosteosarcomaoflimbsinchildrenandyoungadults:thefirststudyoftheEuropeanosteosarcomaintergroup.J.Clin.Oncol.10(1992)1579-15912.SouhamiRLetal.Randomizedtrialoftworegimensofc...[繼續(xù)閱讀]

    1.ClarkJIetal.Amulti-institutionalphaseIItrialofanovelinpatientscheduleofcontinuousinterleukin-2withinterferona-2binadvancedrenalcellcarcinoma:majordurableresponsesinalesshighlyselectedpatientpopulation.Ann.Oncol.13(2002):606-6132.AtzpodienJetal.interleuk...[繼續(xù)閱讀]

    1.BamiasAetal.Docetaxelandcisplatinwithgranulocytecolony-stimulatingfactor(G-CSF)versusMVACwithG-CSFinadvancedurothelialcarcinoma:amulticenter,randomized,phaseIIIstudyfromtheHellenicCooperativeOncologyGroup.J.Clin.Oncol.22(2004):220-2282.VonderMaaseH,etal...[繼續(xù)閱讀]

    1.LoehrerPJ,etal.Vinblastineplusifosfamidepluscisplatinasinitialsalvagetherapyinrecurrentgermcelltumor.JClinOncol.16(1998):2500-25042.HudesGR,etal.Paclitaxelplusestramustineinmetastatichormone-refractoryprostatecancer.SeminOncol.2(1995):41-553.WhitneyCW,e...[繼續(xù)閱讀]

    1.JohnstonSR,etal.RandomizedphaseIItrialofBCDTcarmustine(BCNU),cisplatin,dacarbazine(DTIC)andtamoxifenwithorwithoutinterferonalpha(IFN-alpha)andinterleukin(IL-2)inpatientswithmetastaticmelanoma.BrJCancer.77(1998):1280-12862.EtonO,etal.Sequentialbiochemoth...[繼續(xù)閱讀]